Synthesis and biological evaluation of 2-(4-methylsulfonyl phenyl) indole derivatives: Multi-target compounds with dual antimicrobial and anti-inflammatory activities

Ahmed Shaker (✉ Ph.ahmedshaker@yahoo.com)

Nahda University <https://orcid.org/0000-0002-6260-5385>

Eman K. A. Abdelall

Beni Suef University Faculty of Pharmacy

Khaled R. A. Abdellatif

Beni Suef University Faculty of Pharmacy

Hamdy M. Abdel-Rahman

Assiut University Faculty of Pharmacy

Research article

Keywords: antimicrobial, indomethacin analogues, COX-2 inhibitors, nitric oxide, anti-inflammatory

Posted Date: February 12th, 2020

DOI: <https://doi.org/10.21203/rs.2.17036/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Chemistry on March 30th, 2020. See the published version at <https://doi.org/10.1186/s13065-020-00675-5>.

Abstract

Three series of 2-(4-methylsulfonylphenyl) indole derivatives have been designed and synthesized. The synthesized compounds were evaluated for their antimicrobial, COX inhibitory and anti-inflammatory activities. Compound 7g was identified to be the most potent antibacterial candidate against strains of MRSA, *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii*, respectively with safe therapeutic dose. Compounds 7a-k, 8a-c and 9a-c showed good anti-inflammatory activity with high selectivity toward COX-2 in comparison with reference drugs indomethacin and celecoxib. Compounds 9a-c were found to release moderate amounts of NO to decrease the side effects associated with selective COX-2 inhibitors. A molecular modeling study for compounds 7b, 7h, and 7i into COX-2 active site correlated with results of in vitro COX-2 inhibition assays.

1. Introduction

Bacterial resistance reached a dangerous level due to the misuse of antibiotics thus searching for new antimicrobial agents is a significant issue [1]. Furthermore, the administration of multiple drugs to relieve inflammation associated with a bacterial infection may have some secondary health problems and may increase adverse effects [2]. Unfortunately, few drugs possessed these two activities in a single compound. Therefore, there are continuous trails to develop a monotherapy against inflammation due to microbial infection (dual antimicrobial / anti-inflammatory agent) with minimal adverse effects and high safety margin [3].

The nonsteroidal anti-inflammatory drugs (NSAIDs) are used as the primary remedy for pain, fever, and inflammation through inhibition of cyclooxygenase (COX) enzymes [4-6]. Selective COX-2 inhibitor drugs like valdecoxib **I**, celecoxib **II** and rofecoxib **III** relieve inflammation without any gastric side effects [7] (**Fig. 1**). Despite less gastric irritation of selective COX-2 inhibitors, they showed a few cardiovascular issues consisting of myocardial infarction and high blood pressure [8, 9], leading to the withdrawal of both rofecoxib and valdecoxib from the market [10]. The cause of cardiovascular issues may be due to inhibition of vasodilatory prostacyclin (PGI₂) and an increase in the level of platelet activator thromboxane A₂ (TxA₂) [11]. Nitric oxide (NO) showed vasodilator activity and inhibition of platelet aggregation [12]. Accordingly, attachment of NO donor moiety to selective COX-2 inhibitors may be beneficial to overcome the cardiovascular side effects [13, 14].

A lot of biologically aryl hydrazone derivatives with antimicrobial activity are found in many literatures [15-17] which include nitrofurantoin **IV** [18, 19]. Additionally, indole-based indomethacin **V** is a potent NSAID used for the treatment of inflammatory diseases such as rheumatoid arthritis and osteoarthritis [20]. Still, due to its high selectivity for COX-1 inhibition and its acidic nature, it had an apparent ulcerogenic effect [21].

Herein, we aimed to make molecular hybridization of the indole part of indomethacin with *p*-methylsulfonyl phenyl part of selective COX-2 inhibitors to match the overall structure of coxibs [presence

of a diaryl heterocycle bearing one sulfonamide (SO_2NH_2) or methylsulfonyl (SO_2CH_3) group] [22]. Keep in mind the presence of arylhydrazone derivatives at position 3 in indole with the hope to get compounds with dual antimicrobial / anti-inflammatory activity (Fig. 2).

2. Results And Discussion

2.1 Chemistry

The compounds were synthesized through a series of reactions illustrated in **scheme 1, 2**. The reaction of *p*-methylsulfonyl acetophenone (**3**) with 4-un/substituted phenylhydrazine HCl under Fischer indole synthesis conditions yielded indole derivatives (**5a-c**) that are converted to indole-3-carbaldehyde derivatives (**6a-c**) by Vilsmeier Haack's formylation reaction using POCl_3 and DMF (**Scheme 1**).

IR spectra for compounds **6a-c** showed significant bands at $3205\text{--}3320\text{ cm}^{-1}$ of indole NH, $1657\text{--}1670\text{ cm}^{-1}$ of $\text{C}=\text{O}$ and $1150, 1300\text{ cm}^{-1}$ of SO_2 . ^1H NMR spectra showed a signal at δ 10.00 - 10.04 ppm of an aldehydic proton ($\text{H}-\text{C}=\text{O}$), 3.17-3.21 ppm of SO_2CH_3 and 12.92-12.62 ppm of indole NH which is D_2O exchangeable.

Indole-3-carbaldehyde derivatives (**6a-c**) were reacted with 4-substituted phenylhydrazine HCl to give hydrazone derivatives (**7a-k**) in good yield. The structure elucidation of hydrazone derivatives (**7a-k**) was based on IR, ^1H NMR, and ^{13}C NMR spectral data. IR spectra showed bands at $1593\text{--}1597\text{ cm}^{-1}$ for $\text{C}=\text{N}$ and disappearance of the carbonyl absorption band at $1657\text{--}1670\text{ cm}^{-1}$ which confirm hydrazone formation. ^1H NMR spectra showed a signal at δ 8.24-8.36 ppm of hydrazone proton ($\text{H}-\text{C}=\text{N}$), 10.03-10.73 ppm of hydrazone NH which is D_2O exchangeable, 12.00 ppm for NH indole which is D_2O exchangeable and disappearance of an aldehydic proton at δ 10.00 – 10.04 ppm which confirm hydrazone formation. ^{13}C NMR spectra showed a peak at 143-149 ppm of hydrazone carbon ($\text{C}=\text{N}$) which confirm hydrazone formation.

On the other hand, benzimidazole derivatives (**8a-c**) are synthesized from the reaction of Indole-3-carbaldehyde derivatives (**6a-c**) with 4-chloro-*o*-phenylenediamine in the presence of sodium metabisulphite. IR spectra showed bands at $3272\text{--}3382\text{ cm}^{-1}$ (indole NH, benzimidazole NH) and disappearance of the carbonyl absorption band at $1657\text{--}1670\text{ cm}^{-1}$. ^1H NMR spectra showed the disappearance of an aldehydic proton at δ 10.00-10.04 ppm and the appearance of a signal at δ (12.37-12.45) ppm of benzimidazole NH (D_2O exchangeable) in addition to a signal at δ 12.04-12.18 ppm of indole NH (D_2O exchangeable).

Oxime derivatives (**9a-c**) resulted from the reflux of the reaction of Indole-3-carbaldehyde derivatives (**6a-c**) with hydroxylamine HCl. IR spectra lacked the carbonyl absorption band at $1657\text{--}1670\text{ cm}^{-1}$ and showed absorption bands at $3272\text{--}3382\text{ cm}^{-1}$ (NH, OH) and 1597 cm^{-1} ($\text{C}=\text{N}$). ^1H NMR spectra showed a singlet signal at δ 8.32 ppm of azomethine proton $\text{H}-\text{C}=\text{N}$, 10.89 ppm of OH (D_2O exchangeable) in

besides to signal at δ 11.79-12.04 ppm of indole NH (D_2O exchangeable) and disappearance of an aldehydic proton at δ 10.00-10.04 ppm which confirm oxime formation.

2.2 Biological evaluation

2.2.1 Antimicrobial screening

The antimicrobial study was performed by CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and The University of Queensland (Australia). Evaluation of all synthesized compounds for their antimicrobial activities was done against five pathogenic bacteria, *methicillin-resistant Staphylococcus aureus* (ATCC 43300) as Gram-positive bacteria, *Escherichia coli* (ATCC 25922), *Klebsiella pneumonia* (ATCC 700603), *Acinetobacter baumannii* (ATCC 19606) and *Pseudomonas aeruginosa* (ATCC 27853) as Gram-negative bacteria and antifungal activity against two pathogenic fungal strains *Candida albicans* (ATCC 90028) and *Cryptococcus neoformans var. grubii* (H99; ATCC 208821) (**Table 1**).

Results revealed that hydrazone derivatives **7c**, **7e**, **7f**, **7h**, and **7j** have moderate antibacterial activity against Gram-negative *A. baumannii* with growth inhibition 43.29, 43.64, 66.69, 51.82 and 46.23 %, respectively. While the hydrazone derivatives **7a**, **7g**, and **7i** have high antibacterial activity against *MRSA* bacteria and *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* with growth inhibition ranged from 85.76 to 97.76%.

Additionally, the oxime derivatives **9a** showed moderate antibacterial activity against Gram-negative *A. Bunny* with growth inhibition 42.1%, while benzimidazole derivatives (**8a-c**) showed weak antibacterial activity.

On the other hand, all compounds have weak antifungal activity against *C. albicans* and *C. neoformans var. grubii*.

Minimal inhibitory concentrations (MIC $\mu\text{g/mL}$) measurements were performed for compounds with significant microbial growth inhibition (**7a**, **7g**, and **7i**) using ceftriaxone and amphotericin B as a reference drug for antibacterial and antifungal activity, respectively.

As shown in **Table 2**, compounds **7a**, **7g** and **7i** have the best antibacterial activity comparable to that of ceftriaxone against *MRSA*, *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii*, respectively.

The safety margin for the active compounds to human cells was determined through cytotoxicity against human embryonic kidney cell line and hemolysis of human red blood cells. The tested compounds **7a**, **7g**, and **7i** were tolerated and non-toxic to human cells as the cytotoxic and hemolytic dose was higher than the therapeutic dose (**Table 2**).

Compound **7a** lacked general nonspecific toxicity, as the largest therapeutic dose (16 $\mu\text{g/mL}$ against *A. baumannii*) was lower than the cytotoxic and hemolytic concentration (>32, >32 $\mu\text{g/mL}$ respectively).

Also, compound **7g** showed safe therapeutic concentration against all tested microbes except for *A. baumannii* (4 µg/mL) which is near to cytotoxic concentration (4.2 µg/mL). Otherwise, the therapeutic concentration of compound **7i** against all tested microbes was safe except for *A. baumannii* (4 µg/mL), which is higher than the cytotoxic concentration (2.987 µg/mL).

2.2.2 *In vitro* cyclooxygenase (COX) inhibition assay

The *in vitro* assay evaluated the ability of compounds **7a-k**, **8a-c**, and **9a-c** to inhibit Ovine COX-1 and human recombinant COX-2. All tested compounds have weak COX-1 inhibition activity (IC_{50} = 9.14 – 13.2 µM) in comparison with indomethacin (IC_{50} = 0.039 µM). They also exerted potent COX-2 inhibitory activity (IC_{50} = 0.1 – 0.31 µM) with high COX-2 selectivity (SI = 132 – 31.29) in comparison with reference drugs, indomethacin and celecoxib.

Hydrazone derivatives **7a-k** showed potent COX-2 inhibitory activity (IC_{50} = 0.10 – 0.31 µM) with high selectivity (SI = 132 – 31.29) more than other compounds. Likewise, benzimidazole **8a-c** and oxime derivatives **9a-c** showed good COX-2 inhibitory activity (IC_{50} = 0.13 – 0.35 µM) in comparison with reference drugs.

Generally, all tested compounds were more selective toward the COX-2 enzyme (SI = 31.29 - 132) than indomethacin (SI = 0.079) (**Table 3**) because the size of synthesized compounds was too large to fit into the small COX-1 active site in addition to the presence of diaryl structure bearing SO_2CH_3 or SO_2NH_2 group.

2.2.3 *In vivo* anti-inflammatory activity

The results listed in (**Table 4**) showed that compounds **7a-k**, **8a-c**, and **9a-c** offered good anti-inflammatory activity (56.4 – 93.5% reduction of inflammation) after 6 h. in comparison with celecoxib and indomethacin (94.7, 96.6 % reduction of inflammation, respectively) after 6 h.

Hydrazone derivatives (**7a-k**) showed good anti-inflammatory activity (66.3 – 93.5% reduction of inflammation) after 6 h., Compounds that contained two SO_2CH_3 groups or one SO_2CH_3 and one SO_2NH_2 group (**7b**, **7c**, **7d**, **7e**, **7h**, and **7i**) showed a reduction of inflammation by 93.5, 82.5, 78.6, 79.9, 92.7 and 90.1% after 6 h, respectively, more than other derivatives.

Also, benzimidazole and oxime derivatives (**8a-c**, **9a-c**) showed good inhibition of inflammation ranged from 56.4 - 76.2 % after 6 h.

Compounds **7b**, **7c**, **7h** and **7i** that showed the highest COX-2 inhibitory activity (IC_{50} =0.1, 0.11, 0.11 and 0.1 respectively) with high selectivity (S.I. = 124.2, 103.7, 112.7 and 132 respectively) were found to have excellent anti-inflammatory activity (edema inhibition= 93.5, 82.5, 92.7 and 90.1%, respectively) after 6 h.

2.2.4 *In vitro* nitric oxide release

The NO-releasing properties of compounds **9a-c** were assessed in phosphate buffer of pH 7.4 with Griess reagent [23]. As shown in **Table 5**, compounds **9a-c** were found to release moderate amounts of NO compared to the sodium nitrite standard solution, which may explain that the desired action of NO is mediated systemically in the biological system [24]. Therefore, the insertion of nitric oxide releasing group (oxime) can offer a method to decrease the cardiovascular side effects of selective COX-2 inhibitors.

2.2.5 Structure-activity relationship

Presence of arylhydrazone moiety **7a-k** at position 3 of indole can possess antimicrobial activity against strains of Gram-positive *MRSA* bacteria and Gram-negative *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* beside their COX-2 inhibitory activity.

Concerning the anti-inflammatory activity, replacement of methyl group in position 2 in indomethacin by *p*-methylsulfonyl phenyl moiety increased COX-2 selectivity through increasing the interaction with a hydrophobic residue of COX-2 active site [25]. In addition, the presence of two SO₂CH₃ groups or one SO₂CH₃ and one SO₂NH₂ group (**7b**, **7c**, **7d**, **7e**, **7h**, and **7i**) has COX-2 selectivity more than other derivatives.

Replacement of acidic center (CH₂COOH) moiety in position 3 in indomethacin by benzimidazole moiety **8a-c**, as a rigid isostere of *p*-chlorobenzoyl moiety of indomethacin, enhances the anti-inflammatory activity and COX-2 selectivity.

2.3 Molecular modeling

To understand the nature of the interaction of the most active synthesized compounds and COX-2 active site, a molecular docking study was performed using crystal structure data for COX-2 (PDB: ID 3LN1) active site obtained from protein data bank [26]. Molecular modeling of compounds **7h**, **7i**, **7b**, and co-crystallized ligand, celecoxib was performed using MOE 2018.0101 modeling software.

The docking results of compounds **7h**, **7i**, **7b**, and celecoxib were presented in (**Table 6**). Hydrazone derivatives **7b**, **7h**, and **7i** have been fully fitted within COX-2 active site with high affinity (-17.19, -16.71 and -16.42 Kcal/mol, respectively) in assessment with celecoxib (-14.12 kcal/mol). Compounds **7b**, **7h**, and **7i** contained one SO₂CH₃ and one SO₂NH₂ group or two SO₂CH₃ groups that formed hydrogen bonds with different amino acids (Leu338, Arg499, Ser339, Val335, Arg106, and His75). Besides, the indole ring of compound **7h** and **7i** offered hydrophobic interaction with Val509 (**Fig. 3, 4**). Thus, the molecular docking results ensure that compounds **7b**, **7h** and **7i** bind to COX-2 active site with the same manner of celecoxib.

3. Conclusion

Three series of 2-(4-methylsulfonylphenyl) indole derivatives **7a-k**, **8a-c**, and **9a-c** were evaluated for their antimicrobial and anti-inflammatory activities.

The results showed that arylhydrazone derivatives **7a-k** exhibited moderate to good levels of antimicrobial activity. In particular, compounds **7a**, **7g**, and **7i** showed the highest antimicrobial activity against strains of *MRSA* bacteria and many species of Gram-negative with growth inhibition ranged from 85.76% to 97.76%.

Regarding anti-inflammatory activity, all synthesized compounds **7a-k**, **8a-c** and **9a-c** showed potent anti-inflammatory (56.4 – 93.5% reduction of inflammation after 6 h.) and selective COX-2 inhibitory activity (IC_{50} = 0.1 – 0.31 μ M, SI = 132 – 31.29) more than indomethacin. Besides, oxime derivatives **9a-c** showed good selective COX-2 inhibitory activity with moderate *in vitro* nitric oxide release, which can offer valuable drug design to decrease the cardiovascular problems.

The molecular modeling study ensured *in vitro* COX-2 inhibition assay results. Compounds **7b**, **7h**, and **7i** fitted to a COX-2 enzyme similar to celecoxib.

These results suggested that the presence of methylsulfonyl moiety in the indole ring offered an increase in COX-2 selectivity more than the reference drug indomethacin. Also, hybridization of methylsulfonyl and arylhydrazone moiety with an indole ring, providing valuable design for the development of compounds with dual antimicrobial/anti-inflammatory activity. Many investigations are currently undergoing to determine the mechanism of action of these compounds.

4. Experimental

4.1 Chemistry

A Thomas-Hoover capillary apparatus used to determine melting points. Infrared (IR) spectra were recorded as films on KBr plates using the FT-IR spectrometer.

Thin-layer chromatography (Merck, Darmstadt, Germany) was used for monitoring the reaction mixture, purity, and homogeneity of the synthesized compounds. UV was used as the visualizing agent.

^1H NMR and ^{13}C NMR spectra were measured on a Bruker Avance III 400 MHz for ^1H NMR and 100 MHz for ^{13}C NMR (Bruker AG, Switzerland) with BBFO Smart Probe and Bruker 400 AEON Nitrogen-Free Magnet, Faculty of Pharmacy, Beni-Suef University, Egypt in $\text{DMSO}-d_6$ with TMS as the internal standard, where J (coupling constant) values are estimated in Hertz (Hz) and chemical shifts were recorded in ppm on δ scale.

Microanalyses for C, H, and N were carried out on Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA) at the Microanalytical unit of Al Azhar University, Egypt and all compounds were within $\pm 0.4\%$ of the theoretical values.

p-Methylthioacetophenone (**2**) and *p*-methylsulfonyl acetophenone (**3**) and 5-Un/substituted-2-(4-(methylsulfonyl) phenyl)-1 *H*-indole (**5a-c**) were prepared according to a previous procedure [13]. The compounds were confirmed by matching their physical properties with the reported ones.

4.1.1. General procedure for synthesis of 5-substituted-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde 6a-c

A mixture of phosphorous oxychloride POCl_3 (1.53 g, 10 mmol) and DMF (0.73 g, 10 mmol) was stirred for 30 minutes at room temperature, the solution of respective indole (1 mmol) in DMF (5 mL) was added slowly to the mixture which allowed to stir overnight. The reaction mixture was poured into ice-cold water and neutralized with 40% NaOH. The separated solid was filtered, dried and recrystallized from ethyl alcohol (yield: 70-80%).

4.1.1.1. 2-(4-(Methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde (6a)

Yellow solid; Yield 70%; mp 232-235 °C; IR (KBr, cm^{-1}) 3205 (NH), 3065-3042 (CH aromatic), 2929-2871 (CH aliphatic), 1657 (C=O), 1305, 1150 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 3.21 (s, 3H, SO_2CH_3), 7.27-7.36 (m, 2H, indole H-5, H-6), 7.57 (d, 1H, J = 8 Hz, indole H-7), 8.08 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 8.15 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 8.26 (d, 1H, J = 7.6 Hz, indole H-4), 10.04 (s, 1H, aldehydic H), 12.64 (s, 1H, indole NH, D_2O exchangeable). Anal. Calcd for $\text{C}_{16}\text{H}_{13}\text{NO}_3\text{S}$: C, 64.20; H, 4.38; N, 4.68. Found: C, 64.48; H, 4.40; N, 4.84.

4.1.1.2. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde (6b)

Brown solid; Yield 80%; mp 244-246 °C; IR (KBr, cm^{-1}) 3279 (NH), 3059-3029 (CH aromatic), 2927-2856 (CH aliphatic), 1670 (C=O), 1301, 1148 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 2.45 (s, 3H, CH_3), 3.17 (s, 3H, SO_2CH_3), 7.17 (d, 1H, J = 8 Hz, indole H-6), 7.46 (d, 1H, J = 8 Hz, indole H-7), 8.06-8.14 (m, 5H, indole H-4, phenyl H-2, H-3, H-5, H-6), 10.00 (s, 1H, aldehydic H), 12.62 (s, 1H, indole NH, D_2O exchangeable). Anal. Calcd for $\text{C}_{17}\text{H}_{15}\text{NO}_3\text{S}$: C, 65.16; H, 4.82; N, 4.47. Found: C, 65.27; H, 4.68; N, 4.52.

4.1.1.3. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde (6c)

Yellow solid; Yield 72%; mp 195-197 °C; IR (KBr, cm^{-1}) 3320 (NH), 3064-3027 (CH aromatic), 2928-2853 (CH aliphatic), 1661 (C=O), 1302, 1146 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 3.18 (s, 3H, SO_2CH_3), 7.2 (d, 1H, J = 8 Hz, indole H-6), 7.58 (s, 1H, indole H-4), 7.91 (d, 1H, J = 9.6 Hz, indole H-7), 8.09 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 8.14 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 10.00 (s, 1H, aldehydic H), 12.92 (s, 1H, indole NH, D_2O exchangeable). Anal. Calcd for $\text{C}_{16}\text{H}_{12}\text{FNO}_3\text{S}$: C, 60.56; H, 3.81; N, 4.41. Found: C, 60.73; H, 3.72; N, 4.62.

4.1.2. General procedure for synthesis of 5-substituted-3-((2-(4-substituted-phenyl)hydrazono) methyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole 7a-k

A mixture of an ethanolic solution of respective indole-3-carbaldehyde derivative (**6a-c**) (1 mmol) and 4-substituted phenylhydrazine HCl (1 mmol) was heated under reflux for 4-6 hours in the presence of a few drops of glacial acetic acid. After cooling, the reaction mixture was poured into ice-cold water and the separated solid was filtered, dried and recrystallized from methanol (yield: 73-92%).

4.1.2.1. 3-((2-(4-Fluorophenyl)hydrazono)methyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole (7a)

Brown solid; Yield 73%; mp 204-206°C; IR (KBr, cm^{-1}) 3282-3317 (indole NH, hydrazone NH), 3063 (CH aromatic), 2927-2843 (CH aliphatic), 1597 (C=N), 1302, 1148 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 3.26 (s, 3H, SO_2CH_3), 7.04-7.18 (m, 4H, phenyl hydrazone H-3, H-5, indole H-5, H-6), 7.44 (d, 1H, J = 8 Hz, indole H-4), 7.59 (d, 2H, J = 8.4 Hz, phenyl hydrazone H-2, H-6), 7.99 (d, 2H, J = 8.4 Hz, phenyl H-2, H-6), 8.12 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 8.27 (s, 1H, CH), 8.4 (d, 1H, J = 8 Hz, indole H-7), 10.01 (s, 1H, hydrazone NH, D_2O exchangeable), 11.79 (s, 1H, indole NH, D_2O exchangeable); ^{13}C NMR ($\text{DMSO}-d_6$) δ (ppm): 43.0 (SO_2CH_3), 110.4, 111.9, 112.7, 115.2, 120.3, 125.6, 126.2, 128.0, 129.7, 132.1, 135.7, 136.4, 137.3, 140.2, 143.6 (CH=N), 154.7, 157.1. Anal. Calcd for $\text{C}_{22}\text{H}_{18}\text{FN}_3\text{O}_2\text{S}$: C, 64.85; H, 4.45; N, 10.31. Found: C, 65.08; H, 4.33; N, 9.95.

4.1.2.2. 2-(4-(Methylsulfonyl)phenyl)-3-((2-(4-(methylsulfonyl)phenyl)hydrazono)methyl)-1H-indole (7b)

Yellow solid; Yield 85%; mp 228-230°C; IR (KBr, cm^{-1}) 3262-3309 (indole NH, hydrazone NH), 3017 (CH aromatic), 2934-2863 (CH aliphatic), 1593 (C=N), 1299, 1150 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 3.11 (s, 3H, SO_2CH_3), 3.33 (s, 3H, SO_2CH_3), 7.17 (d, 2H, J = 8 Hz, phenyl hydrazone H-3, H-5), 7.24-7.33 (m, 2H, indole H-5, H-6), 7.51 (d, 1H, J = 8 Hz, indole H-4), 7.75 (d, 2H, J = 8 Hz, phenyl hydrazone H-2, H-6), 7.95 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.13 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.3 (s, 1H, CH), 8.4 (d, 1H, J = 8 Hz, indole H-7), 10.72 (s, 1H, hydrazone NH, D_2O exchangeable), 11.98 (s, 1H, indole NH, D_2O exchangeable); ^{13}C NMR ($\text{DMSO}-d_6$) δ (ppm): 43.9 (SO_2CH_3), 44.8 (SO_2CH_3), 110.5, 111.2, 112.2, 121.5, 122.7, 124.1, 125.7, 127.9, 128.7, 129.5, 130.2, 136.8, 137.3, 137.6, 137.8, 140.6, 149.8 (CH=N). Anal. Calcd for $\text{C}_{23}\text{H}_{21}\text{N}_3\text{O}_4\text{S}_2$: C, 59.08; H, 4.53; N, 8.99. Found: C, 59.27; H, 4.68; N, 9.12.

4.1.2.3. 4-(2-((2-(4-(Methylsulfonyl)phenyl)-1H-indol-3-yl)methylene)hydrazinyl)benzene sulfonamide (7c)

Yellow solid; Yield 83%; mp 203-204°C; IR (KBr, cm^{-1}) 3298-3325 (NH_2 , indole NH, hydrazone NH), 3014 (CH aromatic), 2924-2853 (CH aliphatic), 1593 (C=N), 1276, 1089 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 3.11 (s, 3H, SO_2CH_3), 7.17 (d, 2H, J = 8 Hz, phenyl hydrazone H-3, H-5), 7.24-7.33 (m, 2H, indole H-5, H-6), 7.5 (d, 1H, J = 8 Hz, indole H-4), 7.75 (d, 2H, J = 8 Hz, phenyl hydrazone H-2, H-6), 7.95 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.13 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.36 (s, 1H, CH), 8.39 (d, 1H, J = 8 Hz, indole H-7), 10.71 (s, 1H, hydrazone NH, D_2O exchangeable), 11.97 (s, 1H, indole NH, D_2O exchangeable), NH_2 not distinguished; ^{13}C NMR ($\text{DMSO}-d_6$) δ (ppm): 43.9 (SO_2CH_3), 110.5, 111.2, 112.2, 121.5, 122.7, 124.1, 125.7, 127.9, 128.7, 129.5, 130.2, 136.8, 137.3, 137.6, 137.8, 140.6, 149.8 (CH=N). Anal. Calcd for $\text{C}_{22}\text{H}_{20}\text{N}_4\text{O}_4\text{S}_2$: C, 56.39; H, 4.30; N, 11.96. Found: C, 56.45; H, 4.17; N, 12.28.

4.1.2.4. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-3-((2-(4-(methylsulfonyl)phenyl)hydrazono)methyl)-1H-indole (7d)

Brown solid; Yield 85%; mp 262-264°C; IR (KBr, cm^{-1}) 3319-3340 (indole NH, hydrazone NH), 3023 (CH aromatic), 2932-2856 (CH aliphatic), 1595 (C=N), 1300, 1140 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 2.55 (s, 3H, CH_3), 3.11 (s, 3H, SO_2CH_3), 3.31 (s, 3H, SO_2CH_3), 7.12-7.18 (m, 3H, indole H-6, phenyl hydrazone H-3, H-5), 7.4 (d, 1H, $J = 8.4$ Hz, indole H-7), 7.76 (d, 2H, $J = 8.4$ Hz, phenyl hydrazone H-2, H-6), 7.92 (d, 2H, $J = 8$ Hz, phenyl H-2, H-6), 8.11 (d, 2H, $J = 8$ Hz, phenyl H-3, H-5), 8.35 (s, 1H, CH), 8.18 (s, 1H, indole H-4), 10.71 (s, 1H, hydrazone NH, D_2O exchangeable), 11.88 (s, 1H, indole NH, D_2O exchangeable); ^{13}C NMR ($\text{DMSO}-d_6$) δ (ppm): 22.0 (CH_3), 44.0 (SO_2CH_3), 44.8 (SO_2CH_3), 110.1, 111.2, 111.9, 122.2, 125.6, 126.0, 126.8, 127.8, 128.7, 129.5, 129.8, 130.1, 135.7, 136.9, 137.8, 140.6, 149.8 (CH=N). Anal. Calcd for $\text{C}_{24}\text{H}_{23}\text{N}_3\text{O}_4\text{S}_2$: C, 59.86; H, 4.81; N, 8.73. Found: C, 59.67; H, 4.82; N, 8.97.

4.1.2.5. 4-(2-((5-Methyl-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)methylene)hydrazine-yl)benzenesulfonamide (7e)

Yellow solid; Yield 87%; mp 186-188°C; IR (KBr, cm^{-1}) 3300-3341 (NH_2 , indole NH, hydrazone NH), 3023 (CH aromatic), 2927-2854 (CH aliphatic), 1595 (C=N), 1300, 1130 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 3.1 (s, 3H, CH_3), 3.33 (s, 3H, SO_2CH_3), 7.12-7.18 (m, 4H, phenyl hydrazone H-3, H-5, indole H-4, H-6), 7.39 (d, 1H, $J = 8$ Hz, indole H-7), 7.76 (d, 2H, $J = 8$ Hz, phenyl hydrazone H-2, H-6), 7.93 (d, 2H, $J = 8$ Hz, phenyl H-2, H-6), 8.12 (d, 2H, $J = 8$ Hz, phenyl H-3, H-5), 8.18 (s, 2H, NH_2 , D_2O exchangeable), 8.35 (s, 1H, CH), 10.7 (s, 1H, hydrazone NH, D_2O exchangeable), 11.88 (s, 1H, indole NH, D_2O exchangeable); ^{13}C NMR ($\text{DMSO}-d_6$) δ (ppm): 22.0 (CH_3), 43.9 (SO_2CH_3), 110.1, 111.2, 111.9, 122.3, 125.6, 125.9, 127.9, 128.6, 129.5, 129.8, 130.1, 135.7, 136.9, 137.8, 137.8, 140.5, 149.8 (CH=N). Anal. Calcd for $\text{C}_{23}\text{H}_{22}\text{N}_4\text{O}_4\text{S}_2$: C, 57.24; H, 4.60; N, 11.61. Found: C, 57.56; H, 4.53; N, 11.89.

4.1.2.6. 3-((2-(4-Fluorophenyl)hydrazono)methyl)-5-methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole (7f)

Yellow solid; Yield 80%; mp 159-161°C; IR (KBr, cm^{-1}) 3250-3307 (indole NH, hydrazone NH), 3065 (CH aromatic), 2928-2859 (CH aliphatic), 1597 (C=N), 1300, 1146 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 2.49 (s, 3H, CH_3), 3.4 (s, 3H, SO_2CH_3), 7.02 (d, 2H, $J = 8.4$ Hz, phenyl hydrazone H-3, H-5), 7.04-7.1 (m, 3H, phenyl hydrazone H-2, H-6, indole H-7), 7.37 (d, 1H, $J = 8$ Hz, indole H-6), 7.92 (d, 2H, $J = 8$ Hz, phenyl H-2, H-6), 8.1 (d, 2H, $J = 8$ Hz, phenyl H-3, H-5), 8.18 (s, 1H, indole H-4), 8.25 (s, 1H, CH), 10.03 (s, 1H, hydrazone NH, D_2O exchangeable), 11.75 (s, 1H, indole NH, D_2O exchangeable); ^{13}C NMR ($\text{DMSO}-d_6$) δ (ppm): 22.6 (CH_3), 43.6 (SO_2CH_3), 110.4, 111.5, 112.1, 116.2, 122.3, 125.4, 126.1, 127.8, 129.8, 134.6, 135.7, 136.4, 137.2, 140.2, 143.1 (CH=N), 154.7, 157.0. Anal. Calcd for $\text{C}_{23}\text{H}_{20}\text{FN}_3\text{O}_2\text{S}$: C, 65.54; H, 4.78; N, 9.97. Found: C, 65.6; H, 4.6; N, 9.94.

4.1.2.7. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-3-((2-(p-tolyl)hydrazono)methyl)-1H-indole (7g)

Brown solid; Yield 84%; mp 166-168°C; IR (KBr, cm^{-1}) 3214-3306 (indole NH, hydrazone NH), 3023 (CH aromatic), 2926-28658 (CH aliphatic), 1598 (C=N), 1302, 1149 (SO_2); ^1H NMR ($\text{DMSO}-d_6$) δ (ppm): 2.32

(s, 3H, CH₃), 2.48 (s, 3H, CH₃), 3.25 (s, 3H, SO₂CH₃), 6.95-7.07 (m, 3H, indole H-6, phenyl hydrazone H-3, H-5), 7.39 (d, 1H, *J* = 8.4 Hz, indole H-7), 7.62 (s, 2H, NH₂, D₂O exchangeable), 7.80 (d, 2H, *J* = 8.4 Hz, phenyl hydrazone H-2, H-6), 7.92 (d, 2H, *J* = 8.4 Hz, phenyl H-2, H-6), 8.10 (d, 2H, *J* = 8.4 Hz, phenyl H-3, H-5), 8.2 (s, 1H, CH), 8.25 (s, 1H, indole H-4), 9.91 (s, 1H, hydrazone NH, D₂O exchangeable), 11.71 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 20.5 (CH₃), 22.1 (CH₃), 44.0 (SO₂CH₃), 111.0, 111.9, 120.5, 122.5, 125.6, 126.1, 126.8, 127.2, 127.8, 128.1, 129.6, 130.0, 135.2, 136.1, 137.7, 140.7, 144.1 (CH=N). Anal. Calcd for C₂₄H₂₃N₃O₂S: C, 69.04; H, 5.55; N, 10.06. Found: C, 68.82; H, 5.68; N, 10.32.

4.1.2.8. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-3-((2-(4-(methylsulfonyl)phenyl) hydrazono)methyl)-1H-indole (7h)

Bale yellow solid; Yield 92%; mp 187-188°C; IR (KBr, cm⁻¹) 3265-3337 (indole NH, hydrazone NH), 3025 (CH aromatic), 2925-2854 (CH aliphatic), 1593 (C=N), 1321, 1140 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 3.12 (s, 3H, SO₂CH₃), 3.34 (s, 3H, SO₂CH₃), 7.15-7.20 (m, 3H, phenyl hydrazone H-3, H-5, indole H-6), 7.51 (s, 1H, indole H-4), 7.77 (d, 2H, *J* = 8 Hz, phenyl hydrazone H-2, H-6), 7.95 (d, 2H, *J* = 8 Hz, phenyl H-2, H-6), 8.04 (d, 1H, *J* = 8 Hz, indole H-7), 8.14 (d, 2H, *J* = 8 Hz, phenyl H-3, H-5), 8.34 (s, 1H, CH), 10.73 (s, 1H, hydrazone NH, D₂O exchangeable), 12.11 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 44.0 (SO₂CH₃), 44.8 (SO₂CH₃), 107.0, 111.3, 112.1, 113.4, 125.9, 127.9, 129.0, 129.5, 130.2, 134.0, 136.5, 137.4, 139.4, 140.9, 149.7 (CH=N), 157.2, 159.5. Anal. Calcd for C₂₃H₂₀FN₃O₄S₂: C, 56.89; H, 4.15; N, 8.65. Found: C, 57.17; H, 4.23; N, 8.58.

4.1.2.9. 4-(2-((5-Fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)methylene)hydrazinyl) benzene sulfonamide (7i)

Yellow solid; Yield 82%; mp 212-214°C; IR (KBr, cm⁻¹) 3260-3315 (NH₂, indole NH, hydrazone NH), 3026 (CH aromatic), 2927 (CH aliphatic), 1594 (C=N), 1295, 1140 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 3.24 (s, 3H, SO₂CH₃), 7.14 (d, 2H, *J* = 8 Hz, phenyl hydrazone H-3, H-5), 7.51 (s, 1H, indole H-4), 7.67 (d, 1H, *J* = 8 Hz, indole H-6), 7.76 (d, 2H, *J* = 8 Hz, phenyl hydrazone H-2, H-6), 7.91 (s, 2H, NH₂, D₂O exchangeable), 7.95 (d, 2H, *J* = 8 Hz, phenyl H-2, H-6), 8.03 (d, 1H, *J* = 8 Hz, indole H-7), 8.13 (d, 2H, *J* = 8 Hz, phenyl H-3, H-5), 8.34 (s, 1H, CH), 10.62 (s, 1H, hydrazone NH, D₂O exchangeable), 11.99 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 44.0 (SO₂CH₃), 107.0, 110.6, 112.4, 113.5, 125.9, 127.5, 129.0, 129.2, 130.2, 134.0, 135.5, 136.4, 139.4, 140.8, 141.0, 149.7 (CH=N), 157.2. Anal. Calcd for C₂₂H₁₉FN₄O₄S₂: C, 54.31; H, 3.94; N, 11.52. Found: C, 54.67; H, 3.82; N, 11.73.

4.1.2.10. 5-Fluoro-3-((2-(4-fluorophenyl)hydrazono)methyl)-2-(4-(methylsulfonyl)phenyl)-1H-indole (7j)

Yellow solid; Yield 82%; mp 200-202°C; IR (KBr, cm⁻¹) 3217-3250 (indole NH, hydrazone NH), 3065 (CH aromatic), 2928-2863 (CH aliphatic), 1597 (C=N), 1302, 1145 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 3.33 (s, 3H, SO₂CH₃), 7.01 (d, 2H, *J* = 8 Hz, phenyl hydrazone H-3, H-5), 7.09-7.17 (m, 3H, phenylhydrazone H-2, H-

6, indole H-6), 7.5 (s, 1H, indole H-4), 7.94 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.03 (d, 1H, J = 8 Hz, indole H-7), 8.12 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.25 (s, 1H, CH), 10.09 (s, 1H, hydrazone NH, D₂O exchangeable), 11.99 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 44.0 (SO₂CH₃), 107.3, 111.1, 112.0, 112.7, 113.0, 116.3, 125.9, 127.9, 130.1, 134.0, 136.7, 137.9, 140.6, 142.9 (CH=N), 154.7, 157.0, 159.3. Anal. Calcd for C₂₂H₁₇F₂N₃O₂S: C, 62.11; H, 4.03; N, 9.88. Found: C, 62.32; H, 4.11; N, 10.16.

4.1.2.11. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-3-((2-(*p*-tolyl)hydrazone)methyl)-1H-indole (7k)

Brown solid; Yield 75%; mp 151-153°C; IR (KBr, cm⁻¹) 3220-3270 (indole NH, hydrazone NH), 3034 (CH aromatic), 2927, 2860 (CH aliphatic), 1597 (C=N), 1303, 1146 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 2.23 (s, 3H, CH₃), 3.33 (s, 3H, SO₂CH₃), 6.94 (d, 2H, J = 12 Hz, phenyl hydrazone H-3, H-5), 7.07 (d, 2H, J = 12 Hz, phenyl hydrazone H-2, H-6), 7.15 (d, 1H, J = 8 Hz, indole H-6), 7.48 (s, 1H, indole H-4), 7.94 (d, 2H, J = 8 Hz, phenyl H-2, H-6), 8.05 (d, 1H, J = 12 Hz, indole H-7), 8.12 (d, 2H, J = 8 Hz, phenyl H-3, H-5), 8.24 (s, 1H, CH), 10.01 (s, 1H, hydrazone NH, D₂O exchangeable), 11.96 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 20.7 (CH₃), 43.9 (SO₂CH₃), 105.3, 111.4, 112.2, 113.3, 125.9, 126.9, 127.3, 128.2, 129.9, 134.0, 134.8, 137.7, 137.9, 140.5, 144.0 (CH=N), 157.0, 159.3. Anal. Calcd for C₂₃H₂₀FN₃O₂S: C, 65.54; H, 4.78; N, 9.97. Found: C, 65.70; H, 5.03; N, 10.14.

4.1.3. General procedure for synthesis of 2-(5-substituted-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-6-chloro-1H-benzo[d]imidazole 8a-c

A mixture of 4-chloro phenylene diamine (0.142 g, 1 mmol), sodium metabisulfite (0.19 g, 1 mmol) and respective indole-3-carbaldehyde derivative (**6a-c**) (1 mmol) in DMF was heated under reflux for 6 hours. After cooling, the reaction mixture was poured into ice cold water and the separated solid was filtered, dried and recrystallized from ethanol (yield: 60-70%).

4.1.3.1. 5-Chloro-2-(2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-1H-benzo[d]imidazole (8a)

Yellow solid; Yield 60%; mp 210-212 °C; IR (KBr, cm⁻¹) 3285-3382 (indole NH, benzimidazole NH), 3065-3021 (CH aromatic), 2926-2853 (CH aliphatic), 1660 (benzimidazole C=N), 1301, 1149 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 3.27 (s, 3H, SO₂CH₃), 7.19-7.22 (m, 2H, indole H-5, benzimidazole H-6), 7.3 (t, 1H, J = 7.4 Hz, indole H-6), 7.47 (s, 1H, benzimidazole H-4), 7.55 (d, 1H, J = 8 Hz, benzimidazole H-7), 7.69 (s, 1H, indole H-7), 7.89-7.92 (m, 3H, phenyl H-2, H-6, indole H-4), 7.99 (d, 2H, J = 8.4 Hz, phenyl H-3, H-5), 12.18 (s, 1H, indole NH, D₂O exchangeable), 12.45 (s, 1H, benzimidazole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 43.8 (SO₂CH₃), 105.1, 112.4, 116.4, 116.8, 117.5, 120.7, 121.2, 122.5, 123.8, 127.7, 128.0, 129.5, 131.5, 135.3, 136.2, 136.8, 136.9, 140.5, 145.8. Anal. Calcd for C₂₂H₁₆ClN₃O₂S: C, 62.63; H, 3.82; N, 9.96. Found: C, 62.89; H, 3.68; N, 10.24.

4.1.3.2. 5-Chloro-2-(5-fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-1H-benzo[d]imidazole (8b)

Pale yellow; Yield 67%; mp 202-204°C; IR (KBr, cm⁻¹) 3348-3360 (indole NH, benzimidazole NH), 3008-3063 (CH aromatic), 2854-2928 (CH aliphatic), 1659 (benzimidazole C=N), 1300, 1148 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 3.29 (s, 3H, SO₂CH₃), 7.13-7.22 (m, 2H, indole H-6, benzimidazole H-6), 7.46 (d, 1H, *J* = 8 Hz, benzimidazole H-7), 7.55 (s, 1H, indole H-4), 7.66-7.72 (m, 2H, benzimidazole H-4, indole H-7), 7.91 (d, 2H, *J* = 8 Hz, phenyl H-2, H-6), 8.02 (d, 2H, *J* = 8 Hz, phenyl H-3, H-5), 12.25 (s, 1H, indole NH, D₂O exchangeable), 12.37 (s, 1H, benzimidazole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 43.9 (SO₂CH₃), 105.4, 106.3, 112.1, 113.6, 117.3, 118.3, 122.0, 123.8, 125.2, 127.7, 129.7, 133.5, 136.6, 138.1, 140.4, 140.9, 141.9, 146.3, 149.0. Anal. Calcd for C₂₂H₁₅ClFN₃O₂S: C, 60.07; H, 3.44; N, 9.55. Found: C, 60.31; H, 3.20; N, 9.79.

4.1.3.3. *5-Chloro-2-(5-methyl-2-(4-(methylsulfonyl)phenyl)-1H-indol-3-yl)-1H-benzimidazole (8c)*

Yellow solid; Yield 70%; mp 217-219 °C; IR (KBr, cm⁻¹) 3272-3322 (indole NH, benzimidazole NH), 3192, 3072 (CH aromatic), 2927, 2857 (CH aliphatic), 1620 (benzimidazole C=N), 1301, 1149 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 2.43 (s, 3H, CH₃), 3.27 (s, 3H, SO₂CH₃), 7.12 (d, 1H, *J* = 8.4 Hz, indole H-6), 7.2 (d, 1H, *J* = 8.4 Hz, benzimidazole H-6), 7.43-7.47 (m, 2H, indole H-7, benzimidazole H-7), 7.68-7.71 (m, 2H, indole H-4, benzimidazole H-4), 7.88 (d, 2H, *J* = 8.4 Hz, phenyl H-2, H-6), 7.98 (d, 2H, *J* = 8.4 Hz, phenyl H-3, H-5), 12.04 (s, 1H, indole NH, D₂O exchangeable), 12.45 (s, 1H, benzimidazole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 21.7 (CH₃), 43.8 (SO₂CH₃), 104.7, 112.1, 113.2, 118.4, 118.6, 120.1, 122.7, 125.5, 126.2, 127.6, 128.3, 129.4, 130.0, 134.3, 135.2, 136.1, 137.0, 140.4, 145.7. Anal. Calcd for C₂₃H₁₈ClN₃O₂S: C, 63.37; H, 4.16; N, 9.64. Found: C, 63.24; H, 4.25; N, 9.88.

4.1.4. *General procedure for synthesis of 5-un/substituted-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime 9a-c*

A mixture of an ethanolic solution of respective indole-3-carbaldehyde derivative (**6a-c**) (1 mmol) and hydroxylamine HCl (0.08 g, 1 mmol) was heated under reflux for 4-6 hours in the presence of a few drops of pyridine. After cooling, the reaction mixture was poured into ice-cold water and the separated solid was filtered, dried and recrystallized from ethanol (yield: 55-70%).

4.1.4.1. *2-(4-(Methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime (9a)*

Yellow solid; Yield 62%; mp 199-201°C; IR (KBr, cm⁻¹) 3282-3385 (indole NH, OH), 3010-3028 (CH aromatic), 2928-2951 (CH aliphatic), 1596 (C=N), 1302, 1146 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 3.31 (s, 3H, SO₂CH₃), 7.16 - 7.26 (m, 2H, indole H-5, H-6), 7.48 (d, 1H, *J* = 8 Hz, indole H-7), 7.89 (d, 2H, *J* = 8 Hz, phenyl H-2, H-6), 8.10-8.12 (m, 3H, phenyl H-3, H-5, indole H-4), 8.32 (s, 1H, CH), 10.89 (s, 1H, OH, D₂O exchangeable), 11.96 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 44.2 (SO₂CH₃), 106.4, 112.7, 122.4, 125.7, 126.2, 127.9, 129.0, 129.9, 135.6, 136.7, 137.7, 140.7, 143.3 (CH=N). Anal. Calcd for C₁₆H₁₄N₂O₃S: C, 61.13; H, 4.49; N, 8.91. Found: C, 61.48; H, 4.61; N, 8.62.

4.1.4.2. 5-Fluoro-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime (9b)

Yellow solid; Yield 55%; mp 226-228°C; IR (KBr, cm⁻¹) 3366-3463 (indole NH, OH), 3013-3029 (CH aromatic), 2918-2997 (CH aliphatic), 1598 (C=N), 1298, 1143 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 3.3 (s, 3H, SO₂CH₃), 7.12 (d, 1H, *J* = 8 Hz, indole H-6), 7.48 (s, 1H, indole H-4), 7.8 (d, 1H, *J* = 8 Hz, indole H-7), 7.89 (d, 2H, *J* = 8 Hz, phenyl H-2, H-6), 8.11 (d, 2H, *J* = 8 Hz, phenyl H-3, H-5), 8.31 (s, 1H, CH), 10.89 (s, 1H, OH, D₂O exchangeable), 12.04 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 43.9 (SO₂CH₃), 107.2, 112.2, 113.3, 126.2, 128.0, 129.5, 133.8, 136.3, 139.3, 140.5, 144.0 (CH=N), 157.1, 159.4. Anal. Calcd for C₁₆H₁₃FN₂O₃S: C, 57.82; H, 3.94; N, 8.43. Found: C, 57.58; H, 4.06; N, 8.75.

4.1.4.3. 5-Methyl-2-(4-(methylsulfonyl)phenyl)-1H-indole-3-carbaldehyde oxime (9c)

Yellow solid; Yield 70%; mp 212-214°C °C; IR (KBr, cm⁻¹) 3362 (indole NH, OH), 3025-3060 (CH aromatic), 2857-2928 (CH aliphatic), 1597 (C=N), 1300, 1145 (SO₂); ¹H NMR (DMSO-*d*₆) δ (ppm): 2.42 (s, 3H, CH₃), 3.29 (s, 3H, SO₂CH₃), 7.09 (d, 1H, *J* = 8 Hz, indole H-7), 7.36 (d, 1H, *J* = 8 Hz, indole H-6), 7.86 (d, 2H, *J* = 8 Hz, phenyl H-2, H-6), 7.94 (s, 1H, indole H-4), 8.09 (d, 2H, *J* = 8 Hz, phenyl H-3, H-5), 8.31 (s, 1H, CH), 10.8 (s, 1H, OH, D₂O exchangeable), 11.79 (s, 1H, indole NH, D₂O exchangeable); ¹³C NMR (DMSO-*d*₆) δ (ppm): 21.7 (CH₃), 44.0 (SO₂CH₃), 107.4, 111.8, 122.2, 125.4, 126.2, 127.7, 129.0, 129.9, 135.5, 136.7, 137.7, 140.5, 144.3 (CH=N). Anal. Calcd for C₁₇H₁₆N₂O₃S: C, 62.18; H, 4.91; N, 8.53. Found: C, 62.42; H, 4.83; N, 8.79.

4.2 Biological evaluation

4.2.1 Antimicrobial and antifungal activities

The antimicrobial and antifungal screening was performed according to CO-ADD (The Community for Antimicrobial Drug Discovery) procedures [27].

4.2.2 COX-1/COX-2 inhibition colorimetric assay

Measurement of the ability of the synthesized compounds to inhibit COX isozymes by using colorimetric COX (ovine) inhibitor screening assay kit (Kit catalog number 760111, Cayman Chemical, Ann Arbor, MI, USA) following the manufacturer's instructions and as mentioned before [28].

4.2.3 Carrageenan-induced rat edema assay

Pretreatment of rats with compounds **7a-k**, **8a-c**, and **9a-c** before injection with carrageenan in rat paw which induces inflammation and then the percentage of paw edema reduction was measured after certain hours according to previously reported procedures [29].

4.2.4 *In vitro* nitric oxide release assay

Different solutions of the tested compounds **9a-c** in DMF were diluted using phosphate buffer (pH 7.4) till a final concentration of 100 μ M (test solutions). To 100 μ l of different test solutions, 100 μ l of N-acetyl cysteine solution was added and the obtained solution was kept in an incubator at 37 °C (treated solutions). The solutions were treated similarly as for a nitrite standard solution with Griess reagent components, 100 μ l of sulphanilamide solution was added to each tube of the treated solution, the mixture was left at 25 °C for 5-10 minutes, protected from light. To this mixture 100 μ l of the NED solution was added, the mixture was again left for 5-10 minutes at 25 °C, protected from light.

The absorbance of the formed purple color, if any, was measured within 30 minutes at λ 546 nm, a blank experiment was performed under the same conditions, the procedure was repeated three times for each tested compound and the average absorbance values were calculated. The corresponding concentration of nitrite was determined by comparison to the nitrite standard calibration curve and the amount of NO released (revealed by the corresponding nitrite concentration) was calculated as a percentage of moles of NO released from 1 mole of the tested compounds.

4.3 Molecular modeling and docking

Molecular modeling studies were performed by using Molecular Operating Environment MOE version 2018.0101. Structures of **7b**, **7h**, and **7i** were built in MOE. The X-ray crystal structure of celecoxib bound to the COX-2 (PDB: ID 3LN1) active site was obtained from the protein data bank at research collaboration for Structural Bioinformatics (RSCB) protein database [PDB].

Preparation of the enzyme for docking by removing the Co-crystallized ligand and water molecules then the enzyme was 3D protonated, in which hydrogen atoms were added to their standard geometry. The conformers generated were docked into the COX-2 receptor with MOE-dock using the triangle matcher placement method and the GBVI/WSA dG scoring function.

A molecular mechanics force field refinement was carried out on the top 30 poses generated. Celecoxib was redocked into the active site of 3LN1 to validate the docking protocol. Amino acid interactions and the hydrogen bond lengths were summarized in (**Table 6**).

Declarations

Availability of data and materials

The data sets and samples of the compounds used during the current study are available from the corresponding author on reasonable request.

Authors' contributions

All authors wrote the final version of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable. (No specific funding or grant).

References

- [1] E. Akbas, I. Berber, Antibacterial and antifungal activities of new pyrazolo [3, 4-*d*] pyridazin derivatives, *European Journal of Medicinal Chemistry*, 40 (2005) 401-405.
- [2] V. Alagarsamy, S. Meena, K. Ramseshu, V. Solomon, K. Thirumurugan, K. Dhanabal, M. Murugan, Synthesis, analgesic, anti-inflammatory, ulcerogenic index and antibacterial activities of novel 2-methylthio-3-substituted-5, 6, 7, 8-tetrahydrobenzo (*b*) thieno [2, 3-*d*] pyrimidin-4 (3*H*)-ones, *European Journal of Medicinal Chemistry*, 41 (2006) 1293-1300.
- [3] A.A. Bekhit, A.M. Farghaly, R.M. Shafik, M.M. Elsemery, A.E.-D.A. Bekhit, A.A. Guemei, M.S. El-Shoukrofy, T.M. Ibrahim, Synthesis, biological evaluation and molecular modeling of novel thienopyrimidinone and triazolothienopyrimidinone derivatives as dual anti-inflammatory antimicrobial agents, *Bioorganic Chemistry*, (2018) 38-46.
- [4] E.K. Abdelall, P.F. Lamie, W.A. Ali, Cyclooxygenase-2 and 15-lipoxygenase inhibition, synthesis, anti-inflammatory activity and ulcer liability of new celecoxib analogues: Determination of region-specific pyrazole ring formation by NOESY, *Bioorganic & Medicinal Chemistry Letters*, 26 (2016) 2893-2899.
- [5] A. Zarghi, L. Najafnia, B. Daraee, O.G. Dadrass, M. Hedayati, Synthesis of 2, 3-diaryl-1, 3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors, *Bioorganic & Medicinal Chemistry Letters*, 17 (2007) 5634-5637.
- [6] T. Zebardast, A. Zarghi, B. Daraie, M. Hedayati, O.G. Dadrass, Design and synthesis of 3-alkyl-2-aryl-1, 3-thiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors, *Bioorganic & Medicinal Chemistry Letters*, 19 (2009) 3162-3165.
- [7] K.R. Abdellatif, E.K. Abdelall, W.A. Fadaly, G.M. Kamel, Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1, 3, 5-triarylpyrazoline and 1, 5-diarylpyrazole derivatives as selective COX-2 inhibitors, *Bioorganic & Medicinal Chemistry Letters*, 26 (2016) 406-412.
- [8] T. Grosser, E. Ricciotti, G.A. FitzGerald, The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs, *Trends in Pharmacological Sciences*, 38 (2017) 733-748.
- [9] H.A. Elshemy, E.K. Abdelall, A.A. Azouz, A. Moawad, W.A. Ali, N.M. Safwat, Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1, 3, 5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC, *European Journal of Medicinal Chemistry*, 127 (2017) 10-21.

- [10] C. Patrono, C. Baigent, Coxibs, traditional NSAIDs, and cardiovascular safety post-precision: What we thought we knew then and what we think we know now, *Clinical Pharmacology & Therapeutics*, 102 (2017) 238-245.
- [11] E.M. Smyth, Thromboxane and the thromboxane receptor in cardiovascular disease, *Clinical Lipidology*, 5 (2010) 209-219.
- [12] S. Xu, G. Wang, Y. Lin, Y. Zhang, L. Pei, H. Yao, M. Hu, Y. Qiu, Z. Huang, Y. Zhang, Novel anticancer oridonin derivatives possessing a diazen-1-ium-1, 2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies, *Bioorganic & Medicinal Chemistry Letters*, 26 (2016) 2795-2800.
- [13] A.M. Shaker, E.K. Abdelall, K.R. Abdellatif, H.M. Abdel-Rahman, Design, synthesis, and biological evaluation of 2-(4-(methylsulfonyl) phenyl) indole derivatives with promising COX-2 inhibitory activity, *Journal of Applied Pharmaceutical Science*, 8 (2018) 001-008.
- [14] K.R. Abdellatif, E.K. Abdelall, R.B. Bakr, Nitric oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents, *Current Topics in Medicinal Chemistry*, 17 (2017) 941-955.
- [15] Ł. Popiołek, Hydrazide–hydrazones as potential antimicrobial agents: overview of the literature since 2010, *Medicinal Chemistry Research*, 26 (2017) 287-301.
- [16] Y. Özkay, Y. Tunalı, H. Karaca, İ. Işıkdag, Antimicrobial activity of a new series of benzimidazole derivatives, *Archives of Pharmacal Research*, 34 (2011) 1427-1435.
- [17] N. Singh, A. Pandurangan, K. Rana, P. Anand, A. Ahamad, A.K. Tiwari, Benzimidazole: A short review of their antimicrobial activities, *International Current Pharmaceutical Journal*, 1 (2012) 119-127.
- [18] G. Verma, A. Marella, M. Shaquiquzzaman, M. Akhtar, M.R. Ali, M.M. Alam, A review exploring biological activities of hydrazones, *Journal Of Pharmacy & Bioallied Sciences*, 6 (2014) 69-80.
- [19] D. Saini, M. Gupta, Hydrazones as potential anticancer agents: An update, *Asian Journal of Pharmacy and Pharmacology*, 4 (2018) 116-122.
- [20] J. Kaur, A. Bhardwaj, Z. Huang, E.E. Knaus, N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation, *Bioorganic & Medicinal Chemistry Letters*, 22 (2012) 2154-2159.
- [21] B.P. Bandgar, R.J. Sarangdhar, S. Viswakarma, F.A. Ahamed, Synthesis and biological evaluation of orally active prodrugs of indomethacin, *Journal of Medicinal Chemistry*, 54 (2011) 1191-1201.
- [22] O. Unsal-Tan, K. Ozadali, K. Piskin, A. Balkan, Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity, *European Journal of Medicinal Chemistry*, 57 (2012) 59-64.

- [23] H.A. El-Sherief, G.E.-D.A. Abuo-Rahma, M.E. Shoman, E.A. Beshr, R.M. Abdel-baky, Design and synthesis of new coumarin–chalcone/NO hybrids of potential biological activity, *Medicinal Chemistry Research*, 26 (2017) 3077-3090.
- [24] G.E.-D.A. Abuo-Rahma, M. Abdel-Aziz, E.A. Beshr, T.F. Ali, 1, 2, 4-Triazole/oxime hybrids as new strategy for nitric oxide donors: Synthesis, anti-inflammatory, ulcerogenicity and antiproliferative activities, *European Journal of Medicinal Chemistry*, 71 (2014) 185-198.
- [25] A.G. Habeeb, P. Praveen Rao, E.E. Knaus, Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere, *Journal of Medicinal Chemistry*, 44 (2001) 3039-3042.
- [26] J.L. Wang, D. Limburg, M.J. Graneto, J. Springer, J.R.B. Hamper, S. Liao, J.L. Pawlitz, R.G. Kurumbail, T. Maziasz, J.J. Talley, The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life, *Bioorganic & Medicinal Chemistry Letters*, 20 (2010) 7159-7163.
- [27] M. Berger, A. Roller, N. Maulide, Synthesis and antimicrobial evaluation of novel analogues of dehydroabietic acid prepared by CH-Activation, *European journal of medicinal chemistry*, 126 (2017) 937-943.
- [28] A.H. Abdelazeem, S.A. Abdelatef, M.T. El-Saadi, H.A. Omar, S.I. Khan, C.R. McCurdy, S.M. El-Moghazy, Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents, *European Journal of Pharmaceutical Sciences*, 62 (2014) 197-211.
- [29] A.O. El-Nezhawy, A.R. Biuomy, F.S. Hassan, A.K. Ismaiel, H.A. Omar, Design, synthesis and pharmacological evaluation of omeprazole-like agents with anti-inflammatory activity, *Bioorganic & Medicinal Chemistry*, 21 (2013) 1661-1670.

Tables

Due to technical limitations the tables are available as a download in the Supplementary Files.

Figures

Valdecoxib
I

Celecoxib
II

Rofecoxib
III

Figure 1

Chemical structures of selective cyclooxygenase-2 (COX-2) inhibitor drugs (I, II, III).

Hybridization of chemical structures of indomethacin V, celecoxib II, nitrofurantoin IV to design indole derivatives 7a-k, 8a-c, and 9a-c.

Binding of celecoxib inside COX-2 active site. a) 2D interaction, the most important amino acids are shown together with their respective numbers. b) The 3D proposed binding mode inside the active site of COX-2 resulted from docking.

Figure 4

Binding of compound 7b inside COX-2 active site. a) 2D interaction, the most important amino acids are shown together with their respective numbers. b) The 3D proposed binding mode inside the active site of COX-2 resulted from docking.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [s1.tif](#)
- [graphicalabstract.tif](#)
- [s2.tif](#)
- [figurescaptions.docx](#)
- [tablesfinalrevised.pdf](#)

- [supplimentarymaterials.docx](#)